CD47在肿瘤中的表达及治疗应用

doi:10.3760/cma.j.issn.1673422X.2014.01.001

摘要/Abstract

摘要： 近年来研究发现，CD47通过上调在肿瘤细胞表面的表达来影响肿瘤的生长与转移，同时，其表达上调预示临床预后较差；而CD47单抗可通过激活适应性免疫及直接介导细胞凋亡等机制抑制肿瘤生长。此外，CD47还具有调节血液系统和胃肠道系统正常组织细胞的放射性损伤修复作用，有望成为肿瘤治疗的新靶点。

关键词: 肿瘤, 细胞凋亡, 放射疗法, 抗原,CD47

Abstract: Recent studies find that upregulation of CD47 expression appears to influence tumor growth and metastasis, as well as, associates with a worse clinical prognosis. AntiCD47 antibodies can inhibit tumor growth by activating adaptive immunity and directly mediating apoptosis. In addition, CD47 can regulate the radiation injury repair of blood system and gastrointestinal system. Therefore, CD47 is expected to become a new target in tumor treatment.

Key words: Neoplasms, Apoptosis, Radiotherapy, Antigens, CD47

杜娇娇, 姚辉, 汪延明. CD47在肿瘤中的表达及治疗应用[J]. 国际肿瘤学杂志, 2014, 41(1): 1-4.

DU Jiao-Jiao, YAO Hui, WANG Yan-Ming. Expression and therapeutic application of CD47 in cancer[J]. Journal of International Oncology, 2014, 41(1): 1-4.

参考文献

［1］ Oldenborg PA. CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease［J］. ISRN Hematol, 2013, 2013:614619. ［2］ Zhao XW, Matlung HL, Kuijpers TW, et al. On the mechanism of CD47 targeting in cancer［J］. Proc Natl Acad Sci USA, 2012, 109(42):E2843. ［3］ Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors［J］. Proc Natl Acad Sci USA, 2012, 109(17):66626667. ［4］ Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma［J］. Oncol Rep, 2012, 28(2):465472. ［5］ Bauer PM, Bauer EM, Rogers NM, et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin1［J］. Cardiovasc Res, 2012, 93(4):682693. ［6］ Rogers NM, Thomson AW, Isenberg JS. Activation of parenchymal CD47 promotes renal ischemiareperfusion injury［J］. J Am Soc Nephrol, 2012, 23(9):15381550. ［7］ Odièvre MH, Bony V, Benkerrou M, et al. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease［J］. Haematologica, 2008, 93(4):502510. ［8］ SotoPantoja DR, Stein EV, Rogers NM, et al. Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47［J］. Expert Opin Ther Targets, 2013, 17(1):89103. ［9］ Chao MP, Weissman IL, Majeti R. The CD47SIRPα pathway in cancer immune evasion and potential therapeutic implications［J］. Curr Opin Immunol, 2012, 24(2):225232. ［10］ Hatherley D, Graham SC, Turner J, et al. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47［J］. Mol Cell, 2008, 31(2): 266277. ［11］ Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumorinitiating cells［J］. Proc Natl Acad Sci USA, 2009, 106(33):1401614021. ［12］ Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia［J］. Cancer Res, 2011, 71 (4):13741384. ［13］ Chao MP, Alizadeh AA, Tang C, et al. AntiCD47 antibody synergizes with rituximab to promote phagocytosis and eradicate nonhodgkin lymphoma［J］. Cell, 2010, 142(5):699713. ［14］ Uluckan O, Becker SN, Deng H, et al. CD47 regulates bone mass and tumor metastasis to bone［J］. Cancer Res, 2009, 69(7):31963204. ［15］ Chao MP, Tang C, Pachynski RK, et al. Extranodal dissemination of nonhodgkin lymphoma requires CD47 and is inhibited by antiCD47 antibody therapy［J］. Blood, 2011, 118(18):48904901. ［16］ Kim MJ, Lee JC, Lee JJ, et al. Association of CD47 with natural killer cellmediated cytotoxicity of headandneck squamous cell carcinoma lines［J］. Tumour Biol, 2008, 29(1):2834. ［17］ Zhao XW, van Beek EM, Schornagel K, et al. CD47signal regulatory proteinα (SIRPα) interactions form a barrier for antibodymediated tumor cell destruction［J］. Proc Natl Acad Sci USA, 2011, 108(45):1834218347. ［18］ MartinManso G, Galli S, Ridnour LA, et al. Thrombospondin1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells［J］. Cancer Res, 2008, 68(17):70907099. ［19］ Jaiswal S, Chao MP, Majeti R, et al. Macrophages as mediators of tumor immunosurveillance［J］. Trends Immunol, 2010, 31(6):212219. ［20］ Sick E, Jeanne A, Schneider C, et al. CD47 update:a multifaceted actor in the tumour microenvironment of potential therapeutic interest［J］. Br J Pharmacol, 2012, 167(7):14151430. ［21］ SotoPantoja DR, Isenberg JS, Roberts DD. Therapeutic targeting of CD47 to modulate tissue responses to ischemia and radiation［J］. J Genet Syndr Gene Ther, 2011, 2(2):1000105. ［22］ Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47SIRPalpha signalling pathway［J］. Trends Cell Biol, 2009, 19 (2):7280. ［23］ Kaur S, Roberts DD. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor2［J］. Cell Cycle, 2011, 10(1):1012. ［24］ Isenberg JS, Maxhimer JB, Hyodo F, et al. Thrombospondin1 and CD47 limit cell and tissue survival of radiation injury［J］. Am J Pathol, 2008, 173(4):11001112. ［25］ SotoPantoja DR, Miller TW, Pendrak ML, et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy［J］. Autophagy, 2012, 8(11):16281642. ［26］ SotoPantoja DR, Ridnour LA, Wink DA, et al. Blockade of CD47 increases survival of mice exposed to lethal total body irradiation［J］. Sci Rep, 2013, 3:1038. ［27］ Maxhimer JB, SotoPantoja DR, Ridnour LA, et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling［J］. Sci Transl Med, 2009, 1(3):3ra7.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.